This analysis reveals distinct immune landscapes and survival impacts of cancer driver genes in esophageal cancer, highlighting implications for immunotherapy.
Key Points
Lower Tumor Immune Dysfunction and Exclusion scores were observed in cluster 1 of esophageal cancer patients, indicating a distinct immune environment.
Eighteen survival-associated cancer driver genes were identified using univariate regression analysis, contributing to potential biomarker development.
Enrichment analysis indicated that differentially expressed genes between esophageal cancer subtypes were linked to humoral immune response and receptor-ligand activity.
Potential small-molecule drugs targeting these genes were explored, demonstrating promise in future therapeutic strategies for esophageal cancer.